Patents by Inventor Stefan Sjöberg

Stefan Sjöberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8609135
    Abstract: Anthracycline derivatives are suitable for use in cancer therapy and diagnosis. These anthracycline derivatives can be radiolabelled and used as an imaging agent in cancer diagnosis. The radiolabelled anthracycline derivatives can also be used together with a drug delivery system, in particular including a two-step targeting strategy, for treating solid and disseminated tumors. These drug delivery system can advantageously be used for treatment and diagnosis of breast cancer.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: December 17, 2013
    Assignee: Nuclisome AB
    Inventors: Katarina Edwards, Stefan Sjöberg, Jörgen Carlsson, Lars Gedda
  • Publication number: 20100092388
    Abstract: Anthracycline derivatives are suitable for use in cancer therapy and diagnosis. These anthracycline derivatives can be radiolabelled and used as an imaging agent in cancer diagnosis. The radiolabelled anthracycline derivatives can also be used together with a drug delivery system, in particular including a two-step targeting strategy, for treating solid and disseminated tumours. These drug delivery system can advantageously be used for treatment and diagnosis of breast cancer.
    Type: Application
    Filed: October 13, 2009
    Publication date: April 15, 2010
    Inventors: Katarina Edwards, Stefan Sjöberg, Jörgen Carlsson, Lars Gedda
  • Patent number: 6562316
    Abstract: The present invention relates to a drug delivery system with two-step targeting, which comprises a combination: (a) a lipid carrier provided with cell targeting agent(s) to target the drug delivery system to specific cells or tissues; and (b) a drug enclosed in said lipid carrier and provided with a DNA targeting agent to target the drug to the nuclei of specific target cells. Furthermore, the invention relates to a method of cancer therapy in which the above drug delivery system is administered to a cancer patient. The goal is to treat or analyse both large tumour masses as well as small tumour cell clusters and single spread tumour cells. According to the invention, drug uptake in tumours will be markedly increased at the same time as the interaction of the drug with healthy organs and tissues can be minimized. The invention gives potential to convert palliative into curative treatment.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: May 13, 2003
    Inventors: Katarina Edwards, Jörgen Carlsson, Stefan Sjöberg